Form 8-K · Current report
Teradyne 8-K, filed Jul 29, 2026
- Filed
- CIK
- 0000097210
- Accession no.
- 0001193125-26-321933
Summary
Teradyne reported record second-quarter 2026 revenue of $1.329 billion, up 104% from $652 million a year earlier, with GAAP diluted EPS of $2.38 and non-GAAP EPS of $2.47. The company guided third-quarter 2026 revenue to $1.2–1.3 billion, with GAAP EPS of $1.79–$2.09, citing strong AI-related demand.
Key points
- Q2 2026 revenue was $1,329 million: $1,122 million in Semiconductor Test, $107 million in Product Test, and $100 million in Robotics.
- GAAP net income attributable to Teradyne was $374.5 million, or $2.38 per diluted share; non-GAAP net income was $389.0 million, or $2.47 per diluted share.
- Revenue rose 104% and earnings more than 300% from Q2 2025, with record Memory revenue on DRAM strength and a NAND final-test resurgence.
- CEO Greg Smith said wafer fab equipment investment growth sets the stage for continued growth in 2027 and beyond.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On July 28, 2026, Teradyne, Inc. (“Teradyne”) issued a press release regarding its financial results for the second quarter ended June 28, 2026. Teradyne’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release dated July 28, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Exhibit 99.1: EX-99.1 2 ter-ex99_1.htm EX-99.1 Exhibit 99.1 Teradyne Reports Second Quarter 2026 Results •Second consecutive quarter of record revenue, exceeding the high end of our Q2 Guidance •Revenue up…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.